Tianjin TEDA Science & Technology Development Group

Tianjin Harmonicare was established in Tianjin Economic and Technological Development Area (TEDA) in 2002. Its purpose is to develop new drug core technologies with independent intellectual property rights and characteristics based on the Chinese market and aim at the international market, to develop more effective, safer and more economical new drugs for patients, and to make the company one of the important bases for the research and development of first-in-class innovative drugs in China. At present, Tianjin Harmonicare has established drug design research laboratories, medicinal chemistry research laboratories, molecular pharmacology and cellular pharmacology laboratories, pharmacokinetic laboratories, pharmacodynamic laboratories, pharmaceutical process research laboratories and formulation laboratories, and has initially built a complete first-in-class innovative drug research chain. Since its establishment, the company has formed a research and development system with a reasonable combination of senior, middle and junior scientists, a supporting research team for the core function of new drug discovery, and a preliminary mature outsourcing collaboration system. So far, the company has applied for 54 Chinese invention patents, of which 27 have been applied for PCT, and 87 invention patents have been authorized by foreign countries such as the United States, Japan, and Europe, and 17 invention patents have been authorized by domestic patents. The company was recognized as a Tianjin Science and Technology Small and Medium Enterprise and a Binhai New Area Technology Enterprise in 2011, and was recognized as a National Technology Enterprise in 2012. In recent years, the company has undertaken a number of medical research projects funded by multiple countries and the Tianjin Municipal Government. So far, the company has submitted clinical trial research approval applications to the CDE for 4 Class 1.1 new drugs, 1 Class 3 new drug, and 2 Class 4 new drugs. One Class 6 drug has submitted a marketing application to the CDE.